GlaxoSmithKline (GSK) Given a GBX 1,340 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. set a GBX 1,340 ($17.92) price target on GlaxoSmithKline (LON:GSK) in a research report report published on Thursday morning. The brokerage currently has a neutral rating on the stock.

Several other equities research analysts also recently weighed in on GSK. Investec downgraded GlaxoSmithKline to a hold rating and decreased their target price for the stock from GBX 1,800 ($24.07) to GBX 1,390 ($18.59) in a research report on Monday, November 6th. Shore Capital reaffirmed a hold rating on shares of GlaxoSmithKline in a research report on Wednesday, September 20th. reaffirmed a buy rating and issued a GBX 1,970 ($26.34) target price on shares of GlaxoSmithKline in a research report on Wednesday, September 13th. Jefferies Group reduced their price target on GlaxoSmithKline from GBX 1,750 ($23.40) to GBX 1,675 ($22.40) and set a buy rating for the company in a report on Monday, September 18th. Finally, Liberum Capital reduced their price target on GlaxoSmithKline from GBX 1,900 ($25.40) to GBX 1,760 ($23.53) and set a buy rating for the company in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of GBX 1,563.33 ($20.90).

Shares of GlaxoSmithKline (GSK) traded up GBX 21.40 ($0.29) during midday trading on Thursday, hitting GBX 1,361 ($18.20). The stock had a trading volume of 9,290,878 shares, compared to its average volume of 8,460,000. GlaxoSmithKline has a 52 week low of GBX 1,270 ($16.98) and a 52 week high of GBX 1,724.50 ($23.06). The stock has a market capitalization of $67,480.00 and a P/E ratio of 2,835.42.

GlaxoSmithKline (LON:GSK) last issued its earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%. The company had revenue of GBX 784.30 billion during the quarter.

The business also recently declared a dividend, which will be paid on Thursday, January 11th. Stockholders of record on Thursday, November 9th will be given a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.41%. The ex-dividend date is Thursday, November 9th.

In other news, insider Patrick Vallance sold 20,000 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($17.52), for a total transaction of £262,000 ($350,314.21). Also, insider Simon Dingemans purchased 1,076 shares of the company’s stock in a transaction dated Thursday, October 12th. The shares were bought at an average price of GBX 1,527 ($20.42) per share, for a total transaction of £16,430.52 ($21,968.87). Insiders have bought a total of 1,577 shares of company stock worth $2,400,086 over the last quarter.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/05/glaxosmithkline-gsk-given-a-gbx-1340-price-target-at-jpmorgan-chase-co.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply